Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systane PRO in Mild to Moderate Dry Eye Disease
NCT07639034Phase 4Completed
- Sponsor
- Gordon Schanzlin New Vision Institute
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Systane PRO in dry eye disease (DED), sponsored by Gordon Schanzlin New Vision Institute. Primary endpoint: Ocular Surface Disease Index at 30 days. Started Nov 2025; status: completed.
02
Drugs
Systane PRO
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07639034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639034.